- Stereotaxis reported $8.6 million of sales in Q1 which beat estimates by $1.4 million. Yearly growth was 49.8%.
- The company sold another replacement system since the last conference call 2 months ago. There should be another system sale through this hospital network.
- Procedure volumes in Q1 were down 15% from 2019. However, volumes were only down 3% in March (compared to 2019).
- Stereotaxis will submit its catheter to EU regulators in September. Its submission to US regulators will come soon after that.
- Late in the year, the firm will provide supporting evidence for Genesis' applications in adjacent markets.
For further details see:
Stereotaxis Is Set Up For A Great 2021